| |
|
|
|
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
|
|
Vancouver, BC, May 28, 2023--Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced the departure of Neil Klompas, President and Chief Operating Officer. Mr. Klompas joined Zymeworks in 2007 as Chief Financial Officer and served in multiple capacities until being named Chief Operating Officer and President in 2022.
|
|
|
|
|
|
|
|
|
|
|
|
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
|
|
Vancouver, BC, December 21, 2022--Zymeworks Inc., a clinical-stage biotechnology company developing multifunctional biotherapeutics, announced positive topline results from the pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing BTC.
|
|
|
|
|
|
|
|
Zymeworks Provides Corporate Update and Reports Q3 2022 Financial Results
|
|
Vancouver, BC, November 21, 2022--Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported financial results for the third quarter ended September 30, 2022. The company also completed its plan to become a Delaware domiciled corporation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zymeworks Announces Plan To Become A Delaware Corporation
|
|
Vancouver, BC, July 25, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, has announced its intention to become a Delaware corporation ("New Zymeworks"), subject to receipt of necessary shareholder, stock exchange, and court approvals.
|
|
|
|
|
|
|
|
Zymeworks Appoints Dr. Paul Moore As Chief Scientific Officer
|
|
Vancouver, BC, July 21, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer.
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
